Cover Image

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

AbstractBackground Lebrikizumab improved itch, interference of itch on sleep, and quality of life (QoL) in patients with moderate-to-severe atopic dermatitis (AD), in two Phase 3 trials at 16 weeks compared to placebo.Objectives We assess improvements in itch and sleep interference due to itch and t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jennifer Soung (Author), Sonja Ständer (Author), Jan Gutermuth (Author), Ignasi Pau-Charles (Author), Zach Dawson (Author), Fan Emily Yang (Author), Luna Sun (Author), Evangeline Pierce (Author), Hany Elmaraghy (Author), Linda Stein-Gold (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
by: Peter A. Lio, et al.
Published: (2024)

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
by: Gil Yosipovitch, et al.
Published: (2024)

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
by: Adelaide A. Hebert, et al.
Published: (2024)

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis
by: Jennifer Soung, et al.
Published: (2024)

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
by: Jonathan I. Silverberg, et al.
Published: (2024)

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
by: Jonathan I. Silverberg, et al.
Published: (2024)

Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale
by: Alissa Rams, et al.
Published: (2024)

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
by: Amy S. Paller, et al.
Published: (2023)

Criteria Suggestive of Psychological Components of Itch and Somatoform Itch: Study of a Large Sample of Patients with Chronic Pruritus
by: Gudrun Schneider, et al.
Published: (2020)

Distraction From Itch Shows Brainstem Activation Without Reduction in Experimental Itch Sensation
by: Astrid Stumpf, et al.
Published: (2017)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
by: Labib A, et al.
Published: (2022)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
by: Angela J. Okragly, et al.
Published: (2023)

Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program
by: Sonja Ständer, et al.
Published: (2017)

Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions
by: Gil Yosipovitch, et al.
Published: (2019)

Chronic Itch Affects Patients' Ability to Experience Pleasure: Anhedonia in Itchy Disorders
by: Aleksandra Stefaniak, et al.
Published: (2024)

Minimal Clinically Important Difference in Chronic Pruritus Appears to be Dependent on Baseline Itch Severity
by: Claudia Riepe, et al.
Published: (2019)

Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom
by: Evangeline J. Pierce, et al.
Published: (2024)

Prevalence of Itch in German Schoolchildren: A Population-based Study
by: Grigorios Theodosiou, et al.
Published: (2022)

Small-fibre Neuropathy in Patients with Type 2 Diabetes Mellitus and its Relationship with Diabetic Itch: Preliminary Results
by: Aleksandra A. Stefaniak, et al.
Published: (2022)

Tailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment
by: Adam Reich, et al.
Published: (2017)

Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials
by: Gil Yosipovitch, et al.
Published: (2019)

Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
by: Jinger Lin, et al.
Published: (2024)

Itch improvement has a major and comparable effect on the Dermatology Life Quality Index in psoriasis and atopic dermatitis patients
by: Wolf‐Henning Boehncke, et al.
Published: (2024)

Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
by: Akio Tanaka, et al.
Published: (2024)

Acute Itch Induces Attentional Avoidance of Itch-related Information
by: Sarah Etty, et al.
Published: (2022)

An itching plaque
by: Juan Garcias-Ladaria, et al.
Published: (2015)

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
by: Eric L. Simpson, et al.
Published: (2024)

Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
by: José-Manuel Carrascosa, et al.
Published: (2024)

Cyclosporine in cholinergic itch
by: Sumit Sehgal, et al.
Published: (2022)

Oxcarbazepine Monotherapy
by: J Gordon Millichap
Published: (2006)

NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study
by: Koba Kiknavelidze, PhD, et al.
Published: (2021)

Attentional Bias Towards Visual Itch and Pain Stimuli in Itch- and Pain-free Individuals?
by: Jennifer M. Becker, et al.
Published: (2020)

Signal Transducer and Activator of Transcription 3 in Keratinocytes Regulates Histaminergic Itch but Not Nonhistaminergic Itch
by: Takashi Hashimoto, et al.
Published: (2019)

Abrocitinib may improve itch and quality of life in patients with itch‐dominant atopic dermatitis
by: Jonathan I. Silverberg, et al.
Published: (2024)

Burden of adult atopic dermatitis and unmet needs with existing therapies
by: Elizabeth D. Bacci, et al.
Published: (2023)

Outbreak of Swimmer's Itch in Denmark
by: Eva Susanna Tracz, et al.
Published: (2019)

Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023)

Sensitization Mechanisms of Chronic Itch
by: Shi-Ying Jin, et al.
Published: (2019)

The Challenge of Basic Itch Research
by: Earl Carstens, et al.
Published: (2020)

Itch and Psyche: Bilateral Associations
by: Radomir Reszke, et al.
Published: (2020)